PTEN and neoplasm: The assortments present in KRAS/GNAS mutations, in tandem with alterations prevailing in TP53/PIK3CA/PTEN, exhibited 89% and 100% sensitivity and specificity, respectively, for advanced neoplasia, according to NGS findings [107].